RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Viamet Pharmaceuticals, Inc., a world leader in the development of best-in-class therapies targeting metalloenzymes, announced today that Robert Schotzinger, M.D., Ph.D., President and CEO of Viamet, will present an overview of the Company at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 8, beginning at 11:30 a.m. Pacific Time. The presentation will be held in the Elizabethan Ballroom at the Westin St. Francis Hotel.
“It is an honor to be selected to provide an overview of the significant progress made at Viamet during 2012.”
“I am pleased to have the opportunity to present at the largest and most respected healthcare investing conference,” said Dr. Schotzinger. “It is an honor to be selected to provide an overview of the significant progress made at Viamet during 2012.”
About Viamet Pharmaceuticals, Inc. (www.viamet.com)
Viamet discovers and develops best-in-class inhibitors of key metalloenzymes via a proprietary platform, called the Metallophile® Technology. The Metallophile Technology is based on the Company’s world-class expertise in bioinorganic chemistry and an extensive understanding of metalloenzyme structure and function. The Metallophile Technology has enabled Viamet to rapidly build a portfolio of proprietary clinical compounds and drug candidates which address significant unmet medical needs and represent blockbuster commercial potential. The most advanced of these molecules are VT-464, an orally-active small molecule inhibitor of the enzyme CYP17 lyase, which is in phase 1/2 clinical development for the treatment of castration-refractory prostate cancer, and VT-1161, an orally-active small molecule inhibitor of the fungal enzyme CYP51, which recently completed phase 1 clinical testing with a target indication of onychomycosis.